No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
REGN241220C800000
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume324 Open Interest800.00Strike Price0.00Turnover0.00%IV17.38%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-28DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma13631.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Express News | Regeneron Pharmaceuticals Inc : UBS Cuts to Neutral From Buy
UBS Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Cuts Target Price to $738
New opportunities for dividends: searching for future dividend stars.
The performance of dividend Stocks has been less than satisfactory in recent years, but now is the best time for investors to seek new opportunities.
Regeneron Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market
The IL-33 monoclonal antibody developed by Sanofi (SNY.US) and Regeneron (REGN.US) has been clinically approved again in China for the treatment of chronic sinusitis.
The class 1 new drug itepekimab injection, submitted by Sanofi (SNY.US), has been approved for clinical use and is intended for the treatment of patients with chronic rhinosinusitis without nasal polyps (CRSsNP).